-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Cyclacel Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2023.
- Cyclacel Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$1.96M, a 67.6% increase year-over-year.
- Cyclacel Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$13.4M, a 45.6% increase year-over-year.
- Cyclacel Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$22.6M, a 6.4% decline from 2022.
- Cyclacel Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$21.2M, a 14.9% decline from 2021.
- Cyclacel Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$18.5M, a 119% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)